

# Comment on the Importance of Data Transparency, Openness, and Reproducibility in Dissolution Science and Technology

John W. Mauger

Department of Pharmaceutics and Pharmaceutical Chemistry, University of Utah College of Pharmacy, Salt Lake City, UT

e-mail: john.mauger@hsc.utah.edu

A recent editorial published in *Science* by Jeremy Berg emphasizes that “ideas supported by well-defined and clearly described methods and evidence are one of the cornerstones of science” (1). The broad importance of this topic is reflected by a current project entitled *Reproducibility and Replicability in Science* undertaken by the National Academies of Science, Engineering, and Medicine to “assess research and data reproducibility and replicability issues, with a focus on topics that cross disciplines” (2).

In the editorial, Berg notes that the key finding in a cancer biology article published in *Science* could not be reproduced and “this case reinforces the notion that reproducibility, certainly in cancer biology, is quite nuanced, and considerable care must be taken in evaluating both initial reports and reported attempts at extension and replication.” The critical need for data reproducibility also applies to dissolution science and technology, where the results from dissolution studies have implications related to the safety and effectiveness of the drug and the dosage form. Irreproducible dissolution data can lead to out-of-specification test results, initiating costly and time-consuming root cause analysis.

Because dissolution is a physicochemical process, any lack of specificity with respect to the methodology, the dissolution medium, or the solubility of the drug compound can result in questions about reproducibility of the data. One example is incomplete specifications for buffered dissolution medium, described in one case as a pH 4.5 acetate buffer, but with incomplete information about the concentration of the buffer salts being provided. Therefore, the physicochemical properties of the buffer, including buffer capacity and ionic strength, are unknown to the reader and can lead to problems with data reproducibility given the sensitivity of some drug-excipient mixtures to buffer capacity and with cases where drug dissolution is sensitive to buffer concentration (3, 4). Another example involves the solid phase of the

drug solute. Because different crystalline forms, such as solvates or polymorphs, affect the dissolution rate, then lack of information related to the structure of the solid phase may, in turn, influence the interpretation and reproducibility of the results (5).

Author guidelines for journals have been published to promote transparency, openness, and reproducibility (6). These guidelines include eight standards related to areas such as citations, data transparency, analytic methods, research materials, design and analysis, preregistration of studies, preregistration of analysis plans, and replication. Given the importance and relevancy of this topic to dissolution science and technology, it is timely for *Dissolution Technologies* Editorial Board to consider establishing a policy that follows the template provided in *Science*, where “all data, materials and methods necessary to understand and assess, and extend the conclusions of the manuscript must be available to any reader” (1).

## CONFLICT OF INTEREST

The author disclosed no conflicts of interest.

## ACKNOWLEDGEMENTS

The author would like to thank Dr. Kevin S. Warner for his thoughtful comments and valuable insights.


## REFERENCES

1. Berg, J.; Progress on reproducibility. *Science* **2018**, *359*, 9. DOI: 10.1126/science.aar8654.
2. Project Information. Reproducibility and replicability in science. The National Academies website. <https://www8.nationalacademies.org/cp/projectview.aspx?key=49906>. Accessed March 8, 2018.
3. Ramtoola, Z.; Corrigan, O.I. Influence of the buffering capacity of the medium on the dissolution of drug-excipient

- mixtures. *Drug Dev. Ind. Pharm.* **1989**, *15*, 2359–2374. DOI: 10.3109/03639048909052535.
4. Krieg, B. J.; Taghavi, S. M.; Amidon, G. L.; Amidon, G. E. In vivo predictive dissolution: comparing the effect of bicarbonate and phosphate buffer on the dissolution of weak acids and weak bases. *J. Pharm. Sci.* **2015**, *104*, 2894–2904. DOI: 10.1002/jps.24460.
  5. Grant, D. J. W.; Higuchi, T. *Solubility Behavior of Organic Compounds*; John Wiley & Sons: New York, NY, 1990, pp. 32–46.
  6. Nosek, B. A.; Alter, G.; Banks, G. C.; Borsboom, D.; Bowman, S. D.; Breckler, S. J.; Buck, S.; Chambers, C. D.; Chin, G.; Christensen, G.; Contestabile, M.; Dafoe, A.; Eich, E.; Freese, J.; Glennerster, R.; Goroff, D.; Green, D. P.; Hesse, B.; Humphreys, M.; Ishiyama, J.; Karlan, D.; Kraut, A.; Lupia, A.; Mabry, P.; Madon, T.; Malhotra, N.; Mayo-Wilson, E.; McNutt, M.; Miguel, E.; Levy Paluck, E.; Simonsohn, U.; Soderberg, C.; Spellman, B. A.; Turitto, J.; VandenBos, G.; Vazire, S.; Wagenmakers, E. J.; Wilson, R.; Yrakoni, T. Promoting an open research culture. *Science* **2015**, *348*, 1422–1425. DOI: 10.1126/science.aab2374.



## Automated and integrated effectiveness



**PHARMA  
TEST**

**Automated sampling, measuring and result calculation. All in a fully integrated system. For labor simplification. It's "The German Gründlichkeit".**

For over 35 years, Pharma Test has been a household name for the development and production of high-value tablet dissolution testing systems. We offer a complete range from manual instruments, offline systems with fraction collectors to online dissolution systems with automated samplers.

**>> e.g. the Pharma Test Online Automated Dissolution Testing System (ADS) including a 6-14 position dissolution bath and a TIDAS® L diode array spectrometer by J&M with an integrated PC running the fully 21 CFR part 11 compliant WinDiss software. The software was designed with users and offers high flexibility, user-friendliness and data safety. An integrated system set-up that is ideally for sustained release products.**

**[www.pharma-test.com](http://www.pharma-test.com)**